GlassScriptPhysician profile
Ansif H Anwar
NPI 1154568574
$1,506.74
in general payments reported to CMS, 2019-2025
23 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $31.74 · 2021: $207 · 2022: $332 · 2023: $213 · 2024: $267 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $218.86 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $169.53 | 2025 | Camzyos, Eliquis |
| Abbott Laboratories | $168.46 | 2022 | |
| Edwards Lifesciences Corporation | $162.97 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $96.53 | 2023 | Mounjaro |
| Boston Scientific Corporation | $88.34 | 2019-2025 | Farapulse, Watchman Flx |
| Avanos Medical | $87.14 | 2019 | |
| Amgen INC. | $59.49 | 2022-2025 | Repatha |
| Merck Sharp & Dohme LLC | $51.91 | 2024 | Verquvo |
| Abiomed | $49.00 | 2019-2020 | |
| Atricure, INC. | $40.58 | 2023 | |
| Cvrx, INC. | $31.44 | 2023 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $29.66 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $27.61 | 2021-2023 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.51 | 2024 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $26.38 | 2022 | |
| Medtronic, INC. | $26.35 | 2022 | |
| Alnylam Pharmaceuticals INC. | $26.32 | 2022 | |
| Esperion Therapeutics, INC. | $24.98 | 2024 | Nexletol |
| Cardiva Medical, INC. | $24.70 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.98 | 2019 | |
| Astellas Pharma US INC | $22.98 | 2022 | |
| Preventice Services, LLC | $22.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ansif Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.